Biomarkers play a vital role in the development of therapies as well as the diagnosis and personalized treatment of diseases. But finding and validating novel biomarkers remains challenging. Biognosys’ discovery proteomics (HRM-MS™) enables quantification of thousands of proteins per sample and the identification of significantly regulated proteins as biomarker candidates. These candidates can then be validated using our targeted proteomics approach (MRM or PRM), where up to 100 proteins per sample can be accurately quantified by either relative abundance or absolute levels across thousands of samples in a high-throughput mode.
You are likely to benefit if you are looking to:
- Search for new preclinical biomarkers to support your drug development efforts
- Identify new clinical biomarkers for patient stratification for targeted therapies
- Prioritize new protein targets for diagnostic testing of disease progression or response to drug therapy